Krueger W A, Schroeder T H, Hutchison M, Hoffmann E, Dieterich H J, Heininger A, Erley C, Wehrle A, Unertl K
Department of Anesthesiology, Tübingen University Hospital, Tübingen, Germany.
Antimicrob Agents Chemother. 1998 Sep;42(9):2421-4. doi: 10.1128/AAC.42.9.2421.
The pharmacokinetics of meropenem were studied in nine anuric critically ill patients treated by continuous venovenous hemodiafiltration. Peak levels after infusion of 1,000 mg over 30 min amounted to 103.2 +/- 45.9 microgram/ml, and trough levels at 12 h were 9.6 +/- 3.8 microgram/ml. A dosage of 1,000 mg of meropenem twice a day provides plasma drug levels covering intermediately susceptible microorganisms. Further reductions of the dosage might be appropriate for highly susceptible bacteria or when renal replacement therapies with lower clearances are applied.
对9例接受持续静脉-静脉血液透析滤过治疗的无尿重症患者进行了美罗培南的药代动力学研究。在30分钟内输注1000毫克后,峰值水平达到103.2±45.9微克/毫升,12小时的谷值水平为9.6±3.8微克/毫升。每天两次1000毫克的美罗培南剂量可提供覆盖中度敏感微生物的血浆药物水平。对于高度敏感细菌或应用清除率较低的肾脏替代疗法时,可能需要进一步降低剂量。